Creating vaccines and driving value through partnerships and R&D | Novavax
Novavax is a global biotechnology company with a proven vaccine technology, focused on developing our R&D assets and establishing partnerships to help protect health.
Novavax, Inc. is a biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Using innovative proprietary recombinant nanoparticle vaccine technology, Novavax develops vaccines that are potent, safe, and well-tolerated. The company's pipeline includes vaccines for COVID-19, influenza, respiratory syncytial virus (RSV), and other infectious diseases. Novavax's mission is to improve health globally through the discovery, development, and commercialization of vaccines to prevent serious infectious diseases.
1.4M
45000 / day
1.5M
50000 / day
3.8 min
3.2 pages per visit
40%
-
Domain Rating
-
Domain Authority
-
Citation Level
1987
English, etc
Website Key Features
COVID-19 Vaccine
Novavax has developed a COVID-19 vaccine using its recombinant nanoparticle technology to produce the spike protein of the coronavirus, combined with an adjuvant to enhance the immune response.
Influenza Vaccine
The company's influenza vaccine candidate is designed to provide broad protection against seasonal flu strains and potential pandemic influenza viruses.
RSV Vaccine
Novavax is developing a vaccine for respiratory syncytial virus (RSV), a leading cause of severe respiratory infections in infants and older adults.
Recombinant Nanoparticle Technology
This proprietary technology platform enables the production of highly immunogenic nanoparticles that mimic the structure of viruses, leading to potent immune responses.
Adjuvant Technology
Novavax's Matrix-M adjuvant is designed to enhance the immune response to vaccines, potentially leading to higher efficacy and longer-lasting protection.
Global Health Initiatives
Novavax is committed to improving global health by making its vaccines accessible in low- and middle-income countries through partnerships and collaborations.
Clinical Trials
The company conducts extensive clinical trials to evaluate the safety, efficacy, and immunogenicity of its vaccine candidates.
Regulatory Expertise
Novavax has a strong track record of working with regulatory agencies worldwide to advance its vaccine candidates through the approval process.
Manufacturing Capabilities
The company has established manufacturing facilities and partnerships to produce vaccines at scale, ensuring a reliable supply for global distribution.
Research and Development
Novavax invests heavily in R&D to discover and develop new vaccine candidates, leveraging its proprietary technologies and scientific expertise.
Similar Sites and Competitors
Additional information
Headquarters
Gaithersburg, Maryland, United States
Key People
Stanley C. Erck (President & CEO), John A. Herrmann III (CFO), Gregory M. Glenn (President, R&D)
Number of Employees
Approximately 700 (as of 2021)
Stock Ticker
NVAX (NASDAQ)
Website
https://www.novavax.com
Contact Information
Phone: +1-240-268-2000, Email: info@novavax.com
Social Media
LinkedIn, Twitter, YouTube
Awards and Recognitions
Novavax has received various awards and recognitions for its innovative vaccine technologies and contributions to public health.
Partnerships
The company has established strategic partnerships with governments, NGOs, and other biopharmaceutical companies to accelerate vaccine development and distribution.
Sustainability Initiatives
Novavax is committed to sustainability and environmental responsibility in its operations and vaccine production processes.
HTTP headers
Security headers report is a very important part of user data protection. Learn more about http headers for novavax.com